U.S. stocks edge higher after weekly jobless claims; Salesforce gains
Adaptive Biotechnologies (NASDAQ:ADPT) Chief Financial Officer Kyle Piskel sold 162,820 shares of common stock on November 28, 2025, for approximately $3.17 million. The shares were sold in multiple transactions at prices ranging from $19.28 to $19.72. This sale comes as ADPT trades near its 52-week high of $20.76, having delivered an impressive 214% return year-to-date according to InvestingPro data. The stock appears overvalued compared to its Fair Value, with volatility being a key characteristic noted among InvestingPro’s 10+ tips for this biotech company.
On the same day, Piskel also exercised options to acquire a total of 109,114 shares of Adaptive Biotechnologies common stock at prices of $6.55, $7.80, and $12.14, for a total value of $1,253,540. Despite not being profitable over the last twelve months, with EBITDA at -$60.1M, the company has shown strong revenue growth of 42.6%. For deeper insights into ADPT’s financial health and comprehensive analysis, investors can access the detailed Pro Research Report available on InvestingPro, one of 1,400+ US equities covered with expert analysis.
In other recent news, Adaptive Biotechnologies reported impressive financial results for the third quarter of 2025. The company exceeded market expectations with an earnings per share (EPS) of $0.06, compared to the projected -$0.17, resulting in a surprise of 135.29%. Revenue for the quarter reached $94 million, significantly surpassing the anticipated $60.48 million by 55.37%. These results highlight the company’s strong performance in the recent quarter. The earnings announcement was followed by a stock price change, although specific price movements are not discussed here. These developments reflect Adaptive Biotechnologies’ ability to outperform analyst estimates. The company’s financial achievements have been noted by various market analysts. Investors may find these results noteworthy when considering Adaptive Biotechnologies’ recent performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.